Catalent Inc. (CTLT) has become the subject of numerous financial decisions in the recent past. A favored biotech firm, it has touched a new 52-week high in the market despite reporting a Q1 loss and missing revenue estimates. Novo Holdings' acquisition of Catalent has gained attention with expected unconditional EU antitrust approval. However, this $16.5 billion purchase seems to face an unusual degree of opposition including from US Senator Elizabeth Warren and biotech firm Roche. The acquisition process is expected to reach a conclusion by Dec. 6, under the scrutiny of the EU. In the meantime, CTLT's stock continues to fluctuate with stock upgradation to strong buy and downgradation to sell ratings noted. Amid all the buzz, Catalent Inc. has been actively managing its assets; divesting its Somerset, NJ Oral Solids Facility while comfortably surpassing revenue estimates in its fourth quarter earnings with a gross margin up. The company nevertheless continues to bear the burden of loss in Q1, falling short of market expectations. Additionally, the company has delayed the filing of its annual report.
Catalent CTLT News Analytics from Mon, 05 Feb 2024 08:00:00 GMT to Sat, 23 Nov 2024 21:39:06 GMT -
Rating 7
- Innovation -5
- Information 8
- Rumor -2
